TESTOSTERONE hormone
replacement therapy for men is
coming under increased scrutiny as
some concern has emerged around
an association between the therapy
and the potential for increased
cardiovascular (CV) risk, reports
Medscape Medical News.
The US Androgen Study Group,
who published an editorial in
the Journal of Men’s Health, has
urged the US Food and Drug
Administration (FDA) not to add a
CV boxed warning on testosterone
arguing that there are limitations in
the studies influencing its direction.
The FDA is evaluating the data.The above article was sent to subscribers in Pharmacy Daily's issue from 19 May 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 19 May 14
THE Pharmaceutical Society of Australia (PSA) awarded Brooke Shelly the prestigious 2024 PSA MIMS Credentialed Pharmacist of the Year award last Fri at the Credentialed Pharmacist Conference (CPC24) (PD breaking news).
THE Pharmaceutical Society of Australia (PSA) has unveiled a comprehensive membership package designed to provide robust support for credentialed pharmacists throughout their professional journey.
MEDICAL research produces better outcomes when people with lived experience are involved in the process, according to Breast Cancer Network Australia (BCNA).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.